Sumitomo Mitsui Trust Group Inc. Sells 701,887 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Sumitomo Mitsui Trust Group Inc. lowered its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 8.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,465,858 shares of the company’s stock after selling 701,887 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 1.72% of Recursion Pharmaceuticals worth $36,433,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of RXRX. Brighton Jones LLC boosted its stake in Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock worth $137,000 after acquiring an additional 6,699 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Recursion Pharmaceuticals by 627.6% during the first quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock worth $1,423,000 after purchasing an additional 232,038 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Recursion Pharmaceuticals by 7.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock valued at $953,000 after buying an additional 12,372 shares during the period. Finally, Focus Partners Wealth bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at $77,000. 89.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on RXRX shares. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $10.00 to $11.00 in a report on Wednesday, December 17th. Morgan Stanley set a $11.00 price objective on Recursion Pharmaceuticals in a report on Wednesday, December 17th. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $9.40.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $4.36, for a total value of $959,200.00. Following the sale, the director directly owned 6,649,863 shares in the company, valued at approximately $28,993,402.68. The trade was a 3.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Ben R. Taylor sold 21,383 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $4.18, for a total transaction of $89,380.94. Following the transaction, the chief financial officer owned 761,550 shares of the company’s stock, valued at approximately $3,183,279. This represents a 2.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 585,786 shares of company stock valued at $2,558,598. Corporate insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Stock Up 0.6%

Shares of Recursion Pharmaceuticals stock opened at $4.67 on Friday. The firm has a market cap of $2.43 billion, a PE ratio of -2.59 and a beta of 0.95. The business’s 50 day simple moving average is $4.44 and its 200 day simple moving average is $5.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $19.36 million. During the same period last year, the business earned ($0.34) EPS. The business’s quarterly revenue was down 80.1% on a year-over-year basis. On average, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.